Last updated: June 27, 2026
Genzyme v. Sandoz (1:13-cv-01507): Litigation Summary, Parties, Claims, and Practical Patent/Generic-Entry Impact
Genzyme Corporation v. Sandoz Inc., case number 1:13-cv-01507, is a federal patent litigation matter filed in 2013 that centers on exclusivity and infringement issues tied to Sandoz’s proposed generic product. Publicly available docket-level records indicate the case proceeded through the standard stages of patent litigation (pleadings, discovery, and dispositive motions or settlement activity), but the record available here is not sufficient to produce a complete, accurate, claim-by-claim infringement/validity analysis, identify the asserted patents by number, or state the outcome (trial verdict, Rule 50/56 disposition, or settlement) without risking factual error.
What patents were asserted in Genzyme Corporation v. Sandoz (1:13-cv-01507)?
The case caption and docket identifier alone do not provide the asserted patent numbers, expiration dates, or assertion theories (literal infringement vs. equivalents; method-of-use vs. composition) required for an accurate litigation analysis.
Which patent numbers and Orange Book listings were at issue?
A litigation-to-Orange-Book mapping requires at least one of the following, which is not available in the provided information:
- the complaint listing asserted U.S. patents,
- the patent-in-suit entered in a scheduling order, or
- a later Markman or claim construction order identifying construction disputes by asserted claim.
What infringement theories did Genzyme allege against Sandoz in 1:13-cv-01507?
A reliable infringement analysis requires the complaint’s claim chart structure, including:
- asserted independent and dependent claims,
- product labels or proposed product description used for comparison, and
- whether infringement was framed as drug substance, formulation, manufacturing process, or method-of-use.
Without those elements, any characterization would be speculative.
What validity defenses did Sandoz raise in Genzyme v. Sandoz (1:13-cv-01507)?
Patent litigation validity positions typically include one or more of:
- anticipation/obviousness (35 U.S.C. §§ 102/103),
- lack of enablement or written description (35 U.S.C. § 112),
- indefiniteness (35 U.S.C. § 112(b)),
- non-infringement (separate from validity), and
- unenforceability (inequitable conduct).
The case identifier and parties do not supply which defenses were actually pled or litigated.
How did claim construction (Markman) affect the outcome in 1:13-cv-01507?
A claim construction analysis requires:
- the date and forum (court vs. special master) of Markman,
- the specific claim terms construed, and
- the court’s construction results.
Those inputs are not available in the provided information.
When did Genzyme v. Sandoz (1:13-cv-01507) reach dispositive motions or settlement?
A litigation timeline requires docket events including:
- Rule 12/15 motion outcomes (dismissal/amendment),
- summary judgment orders,
- trial scheduling,
- settlement/consent dismissal or stipulation of dismissal dates.
The docket number is not enough to reconstruct those dates with fidelity.
What is the litigation outcome for Genzyme v. Sandoz, case 1:13-cv-01507?
An outcomes section must state one of:
- final judgment for plaintiff or defendant,
- consent judgment,
- dismissal without prejudice,
- dismissal with prejudice,
- entry of a stipulated injunction,
- settlement with license terms, or
- termination based on jurisdictional or procedural grounds.
Those disposition facts are not available in the provided information.
How does this case impact Sandoz’s generic entry risk for the drug in question?
Patent litigation risk hinges on at least four concrete elements:
- the patent-in-suit(s) and remaining term at the time of decision,
- whether the asserted claims were found infringing or not infringed,
- whether the patents were held invalid or enforceable, and
- whether any court injunction delayed FDA approval or launch.
None of these can be stated accurately from the information supplied.
Which companies’ biosimilar or generic programs were indirectly affected?
Indirect impact analysis depends on:
- which active ingredient and dosage form were at issue,
- whether other ANDA or biosimilar applicants were stayed,
- whether the case used a platform claim set covering multiple manufacturers.
The case identifier does not establish the drug program.
Key takeaways
- Case Genzyme Corporation v. Sandoz Inc. (1:13-cv-01507) is a U.S. patent litigation matter involving a Sandoz generic entry challenge.
- The supplied information does not include asserted patent numbers, infringement claims, validity arguments, claim construction outcomes, or final disposition, so a complete and accurate litigation analysis cannot be produced without introducing errors.
FAQs
- What is the court and jurisdiction for Genzyme v. Sandoz 1:13-cv-01507?
- Was Genzyme’s case based on composition, formulation, method-of-use, or manufacturing process claims?
- Did the court issue a Markman order in 1:13-cv-01507, and what terms were construed?
- Was the case resolved by judgment or by settlement, and did it include an injunction or license?
- How does the outcome of 1:13-cv-01507 affect FDA approval or launch timing for Sandoz’s product?
References (APA)
- Genzyme Corporation v. Sandoz Inc., Case No. 1:13-cv-01507 (Docket information).
